💉 RETATRUTIDE – 60 MG / VIAL – 1 VIAL – ZPHC PHARMA
💉 Product Type
Peptide / Triple Receptor Agonist / Injectable
💉 Active Ingredient
Retatrutide
💉 Description
Retatrutide 60 MG by ZPHC Pharma is a next-generation triple receptor agonist peptide developed to support weight management, metabolic optimization, and glucose regulation. It simultaneously targets GLP-1, GIP, and glucagon receptors, offering a comprehensive approach to appetite control, fat metabolism, and energy expenditure.
Supplied as a 60 MG lyophilized powder in a single vial, it is intended for reconstitution prior to use and is commonly utilized in metabolic and obesity-related research.
💉 Composition & Form
Strength: 60 MG per vial
Form: Lyophilized powder
Presentation: 1 vial
Administration: Subcutaneous injection after reconstitution
💉 Mechanism of Action (How It Works)
Activates GLP-1 receptors to enhance satiety and reduce appetite
Stimulates GIP receptors to improve insulin sensitivity and glucose utilization
Activates glucagon receptors, increasing energy expenditure and fat oxidation
Helps regulate blood glucose levels
Promotes metabolic flexibility and supports body fat reduction while preserving lean body mass
💉 Key Benefits
✅ Supports significant weight management
✅ Promotes fat oxidation and metabolic efficiency
✅ Enhances insulin sensitivity and glucose control
✅ Helps reduce appetite and increase satiety
✅ Supports preservation of lean muscle mass during weight loss
✅ Triple-receptor mechanism for comprehensive metabolic support
💉 Side Effects
⚠ Nausea
⚠ Vomiting
⚠ Diarrhea or constipation
⚠ Decreased appetite
⚠ Injection-site irritation
⚠ Headache or fatigue
⚠ Temporary gastrointestinal discomfort during dose escalation
💉 Contraindications
❌ Pregnancy or breastfeeding
❌ History of medullary thyroid carcinoma (MTC)
❌ Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2)
❌ Known hypersensitivity to peptide components
❌ Severe gastrointestinal disorders unless medically supervised
💉 Technical Summary
| Property | Details |
|---|---|
| Scientific Name | Retatrutide |
| Classification | Triple GLP-1 / GIP / Glucagon Receptor Agonist |
| Dosage Form | Lyophilized Powder |
| Strength | 60 MG / Vial |
| Administration | Subcutaneous Injection |
| Storage | Refrigerate at 2–8°C after reconstitution |
| Research Grade | For research purposes where applicable |
💉 Manufacturer
ZPHC PHARMA
| Brands | ZPHC PHARMA |